Value of neutrophil-lymphocyte ratio combined with PI-RADS v2.1 in the diagnosis of clinically significant prostate cancer
Objective To investigate the neutrophil-lymphocyte ratio(NLR)combined with Prostate Imaging Reporting and Data System v2.1(PI-RADS v2.1)in the diagnosis of clinically significant prostate cancer(csPCa).Methods Clinical data of 130 patients undergoing B-ultrasound-guided transperineal prostate biopsy in Shanghai 411 Hospital from January 2022 to January 2024 were retrospectively analyzed to evaluate the diagnostic value of NLR combined with PI-RADS v2.1 apparent diffusion coefficient(ADC)on csPCa,with pathological results of prostatic needle biopsy as the gold standard for diagnosis.ROC curve was used to evaluate the diagnostic performance of NLR combined with PI-RADS v2.1 ADC for csPCa.Results Among the 130 patients,82 cases had csPCa(csPCa group).Compared with the control group,the age of patients in csPCa group was higher,the ADC of PI-RADS v2.1 was lower,and the NLR was higher,all with statistically significant differences(all P＜0.05).The AUC corresponding to PI-RADS v2.1 ADC,NLR and NLR+PI-RADS v2.1 ADC were 0.822,0.647 and 0.871,respectively.Meanwhile,NLR+PI-RADS v2.1 ADC had the highest sensitivity and specificity,which were 0.768 and 0.813,respectively.Conclusion Both NLR and PI-RADS v2.1 ADC can be used as independent predictors of csPCa,and NLR combined with PI-RADS v2.1 ADC show a high performance in diagnosing csPCa.
Clinically significant prostate cancerNeutrophil-lymphocyte ratioProstate Imaging Reporting and Data System v2.1Transperineal prostate biopsy
万方数据
维普
